Last Updated : May 7, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Enhertu | trastuzumab deruxtecan | Metastatic HER2 positive breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Yondelis | Trabectedin | Metastatic Liposarcoma or Leiomyosarcoma | Do not reimburse | Complete | ||
Cotellic | Cobimetinib | Metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | Pembrolizumab | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Mekinist | Trametinib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo & Yervoy in combo | Nivolumab & Ipilimumab in combo | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Zelboraf | Vemurafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete |